triple agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
The development of myasthenia gravis in people without myasthenia gravis appeared to be more likely in people over 60 years of age. Six non-statin cholesterol-lowering drugs, nicotinic acid, cholestyramine, colestipol, colesevelam, alirocumab, and evolocumab, have been used in people without causing or worsening myasthenia gravis. Beta blockers: Beta blockers (i.e., β-blockers) are drugs that block the binding of two stress hormones, epinephrine and norepinephrine, to their target beta receptors. They are used to decrease the heart rate, reduce the force of heart contractions, and relax blood vessels in order to lower blood pressure and reduce the workload on the heart. In one study the odds of an myasthenia gravis exacerbation after taking a beta blocker was increased 2.7-fold compared with people with myasthenia gravis not taking a beta blocker. These exacerbations generally did not occur immediately after their usage and therefore may have reflected other comorbidities in people with myasthenia gravis being treated with beta blockers. In a study of 20 people with myasthenia gravis treated with a beta blocker, 3 who received oral metoprolol, 9 who received intravenous metoprolol, 1 who received oral labetalol, and 9 who received intravenous labetalol, only one (i.e., 5%) of the 20 participants (who received intravenous labetalol) reacted with an exacerbation of myasthenia gravis symptoms.
The Government of the Spanish Republic in exile (Spanish: Gobierno de la República Española en el exilio) was a continuation, in exile, of the government of the Second Spanish Republic following the victory of Francisco Franco's forces in the Spanish Civil War. It existed until the restoration of parliamentary democracy in 1977.
Dichloroacetic acid (DCA), sometimes called bichloroacetic acid (BCA), is the organic compound with formula CHCl2CO2H. It is an analogue of acetic acid, in which 2 of the 3 hydrogen atoms of the methyl group have been replaced by chlorine atoms. Like the other chloroacetic acids, it has various practical applications. The salts and esters of dichloroacetic acid are called dichloroacetates.
Sources: en.wikipedia.org
== Creativity == On the Global Creativity Index for 2015, Thailand ranks 82 of 139 nations (1=best, 139=worst). Thailand's ASEAN partners were ranked: Singapore, 9; Laos, 42; Philippines, 52; Malaysia, 63; Vietnam, 80; Cambodia, 113; Indonesia, 115.
==== Acquired abnormalities ==== Allergic and vasomotor rhinitis – inflammations of the mucous membrane of the nose caused by an allergen, and caused by circulatory and nervous system disorders. Autoimmune system diseases Bites – animal and human Burns – caused by chemicals, electricity, friction, heat, light, and radiation. Connective-tissue diseases Inflammatory conditions Nasal fractures Naso-orbito-ethmoidal fractures – damages to the nose and the eye-sockets; and damage to the bones and the walls of the nasal cavity; it is the ethmoid bone that separates the brain from the nose. Neoplasms – malignant and benign tumors Septal hematoma – a mass of (usually) clotted blood in the septum Toxins – chemical damages caused by inspired substances – e.g. powdered cocaine, aerosol antihistamine medications, et cetera. Traumatic deformities caused by blunt trauma, penetrating trauma, and blast trauma. Venereal infection – e.g., syphilis
== Advertising == A&W does not do national advertising; the primary factor for such being the lack of restaurants in certain parts of the United States. Its first attempt at doing a national television commercial was on June 16, 1969, when it booked for a slot on NBC's Monday Night at the Movies to advertise take-home gallons of root beer. In 1976, A&W Restaurants participated in the Easter Seals Telethon, where money from large root beer mugs was collected by the local restaurant on behalf of the TV station broadcasting the telethon in the area. In 1997, the chain adopted All American Food as its slogan in order to achieve widespread brand recognition. The chain increased its marketing budget in February 2000, eyeing for a new line of burgers in January 2001. For the summer of 2007, the chain launched the Moove to American campaign, which was created to counter competing chains relying exclusively on foreign beef; the campaign started on June 28 with a stunt featuring 35 cows sent on a barge to the Statue of Liberty. The aim was to petition the National Cattlemen's Beef Association to support consumption of U.S. beef. There was also a campaign to set up a new custom burger, with the winner heading over to Louisville to work for its serving in restaurants. A grassroots partnership with Green Bay Packers receiver Greg Jennings began in 2009, where Papa Burgers were sold at a price of 85 cents in Green Bay restaurants if Jennings made a touchdown. Due to its success, the campaign expanded to include all of Wisconsin in 2010.
Sources: en.wikipedia.org
== Reception == In 2015, Entertainment Weekly highlighted the scene where Kirk reads the United States Constitution, as one of the most important moments in that character's life. WhatCulture ranked this episode the 15th worst episode of the Star Trek franchise. In 2016, SyFy included this episode in a group of Star Trek franchise episodes they felt were commonly disliked but "deserved a second chance". In 2017, this episode was rated the 8th worst episode of the Star Trek franchise up to that time, by ScreenRant. In 2018, CBR included this episode on a ranking of episodes they stated were "So Bad They Must Be Seen". CBS News listed "The Omega Glory" as one of the worst episodes of the original series. In 2017, Den of Geek ranked this episode as the 5th worst Star Trek episode of the original series.
Transcription of insulin is regulated by the binding of various transcription factors to the ~400 base pairs before the insulin transcription start site, called the "insulin regulatory sequence". This sequence is made up of several distinct regions with different biochemical properties, each of which serve as binding sites for distinct regulatory proteins. First, multiple A/T-rich sequences, called "A elements", each of which contains a "TAAT" reocognized by homeodomain proteins. These regions are primarily bound by PDX-1, but also Cdx2 and Isl-1. Second, two so-called "C elements" – C1 located 107–118 base pairs before the transcription start site; C2 311–317 base pairs before the start site. C1 is bound by RIPE3b1 via MafA. C2 (also called the "pancreatic islet cell enhancer sequence" or "PISCES") is bound by PAX6. Third, an "E element" (two in rodents) with sequence GCCATCTG is 91–100 base pairs before the transcription start site and binds the helix-loop-helix transcription factors NEUROD1. Lastly, several "cyclic AMP response elements" with sequence TGACGTCA that binds CREB. In humans, a "Z-element" resides 243–292 base pairs before the start site and binds a complex called ZaI, as well as PDX-1 and MafA.
Methods for the incorporation of click reaction partners into systems in and ex vivo contribute to the scope of possible bioconjugation reactions. The development of unnatural amino acid incorporation by ribosomes has allowed for the incorporation of click reaction partners as unnatural side groups on these unnatural amino acids. For example, azidohomoalanine (AHA) is a methionine analog with an azide side group. This azide side group allows cycloalkynes to react to proteins that incorporate this "AHA" unnatural amino acid. In another example, "CpK" is a lysine analog. CpK has a side group including a cyclopropane alpha to an amide bond that serves as a reaction partner to tetrazine in an inverse diels-alder reaction.
A tea made of the leaves and stem has been used to treat tooth pain. For cases of cough and bronchitis, a water extract (decoction) of Mimosa tenuiflora is drunk. A handful of bark in one liter of water is used by itself or in a syrup. The solution is drunk until the symptoms subside. One preliminary clinical study found Mimosa tenuiflora to be effective in treating venous leg ulcerations. Aqueous extracts of Mimosa are widely used for wound healing and burns in Central and South America. Consequently, the products of the plant (generally grouped under the term "Tepezcohuite") have become a popular and easily produced cosmetic ingredient in commercial skincare products.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.